Aim: To discuss cerebral sinovenous thrombosis (CSVT), which is an important mortality and morbidity factor developing in progression of ulcerative colitis (UC) in childhood age, in the light of literature. Results: Twenty four paediatric cases aged between five and 18 years were included in the study.
INTRODUCTION
Cerebral sinovenous thrombosis (CSVT) developing secondary to obstruction in the veins functional in venous drainage of brain is an important morbidity and mortality factor that is quite rarely observed in childhood age. Its incidence is 0.25-0.67/100000 (1-2). Of CSVT cases in this age group; 5-12% show fatal progression while permanent neurological sequelae develop in 61-74% cases (2) . Potential risk factors associated with CSVT in childhood age include prematurity, trauma, chronic inflammatory disorders, surgical operation, cardiac diseases, traumatic venous sinus damage, nephrotic syndrome, malignancy, head and neck infections and dehydration (2) (3) . Risk for cerebrovascular complication in inflammatory bowel disease (IBD), being one of the risk factors of CSVT, is 1.3-3.3% (3) . The development of CSVT demonstrates a three-four-fold elevation in IBD (4) . Its pathogenesis is considered associated with increased inflammatory response, genetic predisposition, loss of procoagulant factors through gastrointestinal system, temporary abnormalities in clotting system, increased levels of Factor V and VIII beside decreased levels of protein S and antithrombin III during disease progression (5) .
This article aimed to discuss risk factors, clinical and laboratory findings, treatment and prognosis of CSVT that is an important and mortality factor in progression of ulcerative colitis (UC) during childhood age, in the light of literature review
MATERIALS AND METHOD

Review method
Pubmed and Google Scholar Search databases were screened in April 2014. This screening was performed using key words "cerebral venous thrombosis in childhood, thrombosis and/or thromboembolism and/or stroke, colitis, ulcerative colitis and/or inflammatory bowel diseases, infant or child or adolescent or paediatric". All of these key words were screened in the databases without a language limitation and all of the potentially related articles were evaluated.
The study investigated the cases below 18 years of age diagnosed UC accompanied with developing CSVT between years 1971 to 2014. The cases were analysed with respect to age, gender, disease progression and treatment, potential risk factors for thrombosis, radiological findings, accompanying symptoms and findings, thrombolytic treatment applications and clinical progressions.
RESULTS
Demographic findings
The study included the 24 child cases followed-up with diagnosis of UC accompanied with developing CSVT (Table I) . Mean ages of the cases were 13.0 ± 3.7 (ranging 5-18) years.
The ratio between female/male was one. Incidence ages of CSVT in female and male children were 13.3 ± 3.9 and 12.7 ± 3.8 years. Llyod-Still et al (6) have reported the youngest case who was a five-year old female patient. Most of the cases (18/24, 75%) were in the adolescent age group (> 10-18 years old). The childhood age group (≤ 10 years old) included six (25%) cases (Table I ). Age at diagnosis and time to development of thrombosis in four cases were not reported. Mean diagnosis age of the reported 20 cases was 11.7 ± 2.7 years and median value of time to development of CSVT after diagnosis of UC was 10.5 months [ranging 0.5-66.0 months] (Table I ). The earliest time to development of thrombosis during disease progression was two weeks as reported by Barclay et al (7) . The longest time to development of CSVT after UC was 66 months (5) . Thrombosis developed during active stage of the disease in 23 (95.8%) cases whereas disease was not in the active stage in only one case. Of the cases; four (16.6%), three (12.5%) and 15 (62.5%) were receiving only 5-ASA, only steroid and combined therapy, respectively. The treatment protocol of two cases had not been reported (Table I) .
Clinical findings
All patients were symptomatic (Table 1) . Analysis of the baseline symptoms revealed the most common application rationales such as headache (19 cases, 79 .1%) and emesis (7 cases, 29.1%).
The accompanying clinical findings were summarized in (Table 2) .
Prothrombotic Risk Factors
The most frequently observed risk for CSVT in the patients with ulcerative colitis was anaemia (14 patients, 58.3%) and thrombocytosis (11 patients, 45.8%). Thrombosis and anaemia were the only detectable risk factors for CSVT in three (12.5%) and two (8.3%) patients, respectively.
Companionship of anaemia and thrombocytosis was present in eight (33.3%) of the cases.
Incidence of risk factor for anaemia in the childhood age group (≤ 10 years old) was 33.3% (2/6) whereas that was 61.1% (11/18) in the adolescent age group. Incidence of risk factor for thrombocytosis in the childhood age group) was 33.3% (2/6) whereas that was 50% (9/18) in the adolescent age group. Among risk factors, inherited thrombotic disorders were detected in 10 (41.6%) cases. The most frequently observed inherited thrombotic disorders were mutation of methylene-tetra-hydro-folate reductase (MTHFR) [3 patients, 12 .5%] and Anti-thrombin III deficiency (3 patients, 12.5%), respectively. Incidence of inherited thrombotic disorders in the childhood age group was 50% (3/6) whereas that was 38.8% (7/18) in adolescent age group.
Risk factors of thromboembolism reported in the cases with UC were shown in the (Table 3) .
Radiological findings
The number of the cases in whom CSVT was encountered in multiple locations was 12 (50.0%).
In the cases with expressed location sites; CSVT was most commonly located in transverse sinus (8 patients, 33.3%), sigmoid sinus (8 patients, 33.3%) and superior sagittal sinus (7 patients, 29.1%), respectively ( Fig. 1) . The most common location in the adolescent age group was transverse sinus whereas the most common in the childhood age group was sagittal sinus.
Treatment and outcome
Heparin, low molecular weight heparin (LMWH), warfarin, aspirin and anti-factor Xa were administered in, respectively nine (47.3%), eight (42.1%), seven (36.8%), two (10.5%) and one (5.2%) of the 19 cases whose treatment protocols were expressed. Warfarin, LMWH and anti-factor Xa were administered after medication with heparin in seven (36.8%), two (10.5%) and one (5.2%) cases, respectively (Tables 1 and Table 4 During follow-up period under heparin therapy, one patient was complicated with heparin induced thrombocytopenia type II but recovered completely after exchanging the anticoagulant to fondaparinux (5) . The treatment protocols of five cases were not expressed (6, 8, 10, 12) while it was expressed that anticoagulant therapy was not administered in two cases because of risk for bleeding (11, 13) (Tables 1 and Table 4 ). Only heparin or LMWH medication was preferred in the three patients whose treatment protocols were expressed in the childhood age group (14-16) [ Table 1 ]. Of the patients who were treated heparin or LMWH; 86.6% (13/15) were healed completely while 13.3 (2/15) were recovered partially (14) . Of the patients who received aspirin treatment; one patient remained hemiplegic (7) whereas the other patient was recovered completely (17) .
It has been reported for the 24 cases followed with CSVT that 19 (79.1%) cases were healed completely whereas neurological sequelae (mild right pronator drift (14) , hemiplegia (7), hemiparesis (14) ) remained in three (12.5%) cases while two (8.3%) cases became exitus (8, 13) . Grand Mal epilepsy was reported as cause of death (13) while development of sepsis after meningitis due to Staphylococcus aureus and Enterobacter cloacae was cause of death in the other exitus patient (8) . Anticoagulant therapy was not given in one of the exitus cases (13) while treatment protocol was not reported in the other exitus case (8) . Of the two cases who were not given anticoagulant therapy because of bleeding risk; one died (13) whereas other cases was recovered completely (11).
Our Case
The 17-year-old female patient applied Paediatric Emergency Department with complaints of meaningless speech and extreme difficulty in expressing herself, understanding words and naming objects that continued for the recent two days, headache, bloody mucus in stool and fatigue that existed for the recent ten days. It has been informed that our patient was diagnosed 1.5 years ago, she has regularly used mesalazine and had two attacks of ulcerative colitis flares, with last one being four months ago, in her medical history. The physical examination of the patient revealed no abnormal finding except Wernicke's aphasia, headache and paleness. (Figs. 2-4) . The LMWH and treatment of intravenous iron were initiated. Erythrocyte transfusion was performed. The tests for thrombosis demonstrated only positive heterozygous MTHFR mutation. The patient whose clinical and radiological findings improved due to treatment of LMWH was discharged to be followed-up in the polyclinic.
DISCUSSION
Cerebral sinovenous thrombosis that may be observed in progression of ulcerative colitis as one of the potential extraintestinal symptoms is an important mortality and morbidity factor (5, 18).
Patterson et al (19) have reported the first thromboembolic complication due to IBD in childhood age. Risk for venous thromboembolism (VTE) in case of IBD ranges between 1-8% in all age groups whereas that risk ranges between 39-41% in the cases applied post-mortem autopsy (20) . VTE in the children with IBD (3). It has been found in our literature review that development of CSVT was mostly detected in the adolescent age group (75%) and female/male ratio was determined equal differently from the cohort studies.
At the same time, time to development of CSVT was approximately, 10.5 months after onset of disease and this situation was similar to the reported values in the literature.
Clinical presentation of CSVT in paediatric population are nonspecific, most commonly including triad headache, emesis, and depressed mental status plus seizures (22) . The symptoms of our study were also similar with the literature.
Risk for thromboembolism increases than normal population in IBD (3). The association
between IBD and thrombosis is not yet completely clarified. Beside studies state that VTE is more frequently seen than Crohn's disease (CD) in progression of UC (3, 20 -21, 23) , some studies suggest that no significant difference was present (20, 24) . Some studies consider VTE as a complication in progression of UC whereas some studies that accept VTE as a finding of the disease are also present (25) . It has been considered that dehidratation, accompanying infections, anaemia, concomitant autoimmune diseases, presence of cyanotic heart disease, co-morbidity of nephrotic syndrome, corticosteroid treatment, use of oral contraceptive, immobility, inherited thrombotic diseases, previous surgical operations, activation of the disease, thrombocytosis, chromosomal disorders and metabolic circumstances such as homocystinuria play role in aetiology of CSVT which develops during progression of UC in the childhood (3, 22, (26) (27) (28) . Its pathogenesis is accepted associated with increased inflammatory response, genetic predisposition, loss of procoagulant factors through gastrointestinal system, temporary abnormalities in clotting system, increased levels of Factor V and VIII beside decreased levels of Protein S and antithrombin III during disease progression (5).
Main causes of thrombocytosis which is accepted as a risk factor in development of CSVT in the patients with IBD are chronic inflammation, acute haemorrhage and use of corticosteroid (26) (27) . It has been stated that essential factor in pathogenesis of thrombocytosis is activation of thrombocytes due to endothelial damage in the wall of gastrointestinal system during acute exacerbations. It has been concluded that inflammatory mediators that increase during endothelial damage elevate potential of VTE as well as activation of thrombocytes (26) .
On the other side, development of VTE in absence of thrombocytosis in the subjects with inflammatory bowel disease make us consider that thrombocytosis doesn't cause exclusively thromboembolic phenomenon (26) (27) . Another effective factor in development of CSVT through thrombocytes is use of corticosteroids in treatment of UC. It has been suggested that these medicines inhibit synthesis of prostacyclin by reducing level of arachidonic acid in the vessel wall and create predisposition to thrombosis by making thromboxanes dominant (29) .
On the other hand, corticosteroids have also inflammatory effect, reducing effect on hypercoagulability and increasing effect on efficacy of heparin as well as thrombogenic effect.
Therefore, effect of steroid treatment in thrombosis is controversial. It has been also shown in the evidence-based studies conducted in the recent years (27, 30 ) that use of corticosteroids does not increase risk for thromboembolism in the patients with and without IBD (17, 27) .
In our study, thrombocytosis was detected in 45.8% of the cases with UC and thrombocytosis was the unique detectable risk factor in only three cases (9-10, 31).
Nonetheless, development of thrombocytosis was present in 47% of the 17 cases who received corticosteroid treatment. The obtained data has shown that thrombocytosis can be rarely solely risk factor for CSVT and that use of corticosteroids doesn't lead to thrombocytosis.
It has been proposed that iron deficiency anaemia is another important factor in aetiology of CSVT and stroke in childhood age (32) (33) . It has been stated that presence of iron deficiency anaemia increases risk for development of vaso-occlusive stroke 3.8-10-fold in childhood age group (33) (34) . In the recent years, available reports conducted on this issue in the related childhood age group are in the form of case presentation (35) (36) (37) . Despite this, role of iron deficiency anaemia in pathogenesis of CSVT is not yet certainly clarified (38) . However, it has been emphasized that thrombocytosis accompany 81% of cases with severe anaemia and this accompanying thrombocytosis leads to CSVT (38) . Risk for development of thrombocytosis is 10.5-fold more in the children with iron deficiency anaemia than the healthy children (34) . On the other side, iron is known as the negative feedback agent for production of thrombocytes (35, 39) . It has been emphasized that low serum iron level causes thrombocytosis by activating megakaryocytes with increased level of erythropoietin and that microcytosis which develops due to iron deficiency contributes to formation of CSVT (35, (39) (40) . It has been emphasized in a research which analysed 65 cases with IBD and cerebral thrombosis that presence of anaemia was detected in approximately half of the cases while anaemia is the unique detectable risk factor in 31% of the cases (27) . Stolz et al have determined in the case-control study including 121 cases with iron deficiency that CSVT was significantly higher than the control group in the cases with Hb level < 9 gr/dL. In this study, thrombocytosis is not found a significant risk factor in development of CSVT while presence of severe anaemia (Hb < 9 gr/dL) was reported as important and independent risk factor [RR 7.79, 95% CI 1.73-35.10, p < 0.008] (38). In our study, the most common risk factor for CSVT in the patients with ulcerative colitis were anaemia (58.3%) and thrombocytosis (45.8%). Thrombocytosis and anaemia were the unique detectable risk factors for CSVT in three (12.5%) and two (8.3%) patients, respectively. Co-morbidity of anaemia and thrombocytosis was present in eight (33.3%) of the cases.
In progression of inflammatory bowel disease, development of thrombosis usually occurs in the acute exacerbations (15, 26) . It has been detected in the studies that 71-100% of cases with IBD accompanied thromboembolism (TE) were in the active disease period (3, 7, (26) (27) 41) . The researchers have pointed out that risk for development of VTE increases 2-3-fold in the patients with active IBD than the ones with IBD in the inactive period and that this risk increases during passage from moderate exacerbation to severe exacerbation (3). It is also considered that time duration is an important factor in development of thrombosis as well as disease activity. It has been reported that cases with medical history of IBD longer than two years generally carry higher risk of thromboembolism than other cases (3). The development of CSVT in the active stage of the disease is associated with increased levels of fibrinogen, prothrombin fragment F1+2, thrombocytes, plasminogen activator inhibitor-1 and soluble thrombomodulin (15) . It has been reported that immobility and fluid loss also contribute in addition to excessive clotting developing due to disease activity (15) . In our study, 95.8% of the cases with UC accompanied with CSVT were found in the active exacerbation stage.
Median value of time to development of CSVT was 10.5 months.
Another risk factor for thrombosis in the patients with UC is inherited thrombophilic disorders (26) . In the childhood age; inherited thrombophilic disorders were determined as risk factors in 36%, 44% and 33% of the cases with venous thromboembolism, ischaemic stroke and IBD accompanied with venous thromboembolism, respectively (3). The most common inherited risk factors for thromboembolism in IBD patients Factor V Leiden mutation, G20220A mutation in the prothrombin gene, and homozygous C677T mutation in the methylenetetrahydrofolate reductase gene (42) . The most frequently investigated factor among these disorders in the recent years was Factor V Leiden mutation. Jackson et al have reported incidence of Factor V Leiden mutation as 5% in the study with 52 cases who had IBD and thromboembolism (43) . The risk of thrombosis increases approximately five-fold in IBD patients with heterozygous for Factor V Leiden mutation and G20220A mutation in the prothrombin gene (27) . Some authors who do not accept these inherited thrombophilic disorders in IBD patients as a risk factor beside main risk caused by the main disease since the report showing the relationship between IBD and thrombophilia are mainly published as a case report (15, 26) . They recommend this issue has to be studied by multicenters, that include a larger number of IBD patients with thrombosis, to clarify the relationship between IBD and inherited thrombophilic disorders (42) . In this review, 41.6% of the cases with UC had inherited thrombophilic disorders.
It is an undeniable reality that risk for venous thrombosis increases in UC. Therefore, it is recommended to apply prophylactic treatment in the recent years to reduce risk for thrombosis in presence of additional risk factors such as immobility, thrombophilia, thrombocytosis (> 750.000/mm 3 ) and severe disease (Pediatric Ulcerative Colitis Activity Index > 45) that accompany UC in the childhood age (3). Also recommendations for dipyridamole therapy as outpatient are available for the selected patients and ones who have these additional risk factors (3, 7) . Prophylactic oral or IV iron therapy are involved in the other preventive recommendations for iron deficiency anaemia that plays a role in aetiology of CSVT.
Oral iron preparations are available for the patients with IBD in whom intravenous iron preparations are contraindicated (27) . However, a consensus on iron prophylaxis has not been established yet.
There is a consensus between guides on administering anticoagulants in acute therapy of CSVT except neonates (44) (45) (46) . The most important effect of the anticoagulants used in treatment of CSVT is prevention of newly developing venous infarction. The greatest conflict of the anticoagulant treatment is causing potential intracranial haemorrhage although it leads to improvement of pulmonary embolism and neurological findings (27) .
In presence of acute ischemic stroke which developed after CSVT, ultra-fractionated (46) . The more commonly preferred treatment protocol in our study was to initiate with UFH and LMWH and to continue with warfarin and LMWH. Except these, rate of the patients who received only LMWH was 25% whereas rate of the patients who received only aspirin was 8.3%. No treatment was given because of risk for bleeding in only two patients.
Paediatric stroke due to CSVT, being 10th leading factor in paediatric deaths, has a mortality rate of 10% (22, (47) (48) . Mortality rate in presence of CSVT accompanying IBD was reported 5.7% (3). Relapse rate for CSVT in childhood age was < %5 while this rate ranges between 15-20% in haemorrhagic stroke and arterial ischemic stroke (22, (47) (48) . A permanent neurological deficit develops in three-fourth of the surviving child cases with CSVT (22) . The partial recovery rate in the cases with CSVT in presence of IBD is 34%. Early and late recurrence are observed in 11% and 10% of these cases, respectively (3). The reported recovery rate without a sequela in the cases with CSVT in presence of UC was 79.2%. Mortality rate was found 8.3% similarly with literature. The partial recovery rate was detected 12.5%.
As a conclusion, IBD is a risk factor for venous thrombosis. The risk for thromboembolism is higher than normal population because of predisposition to hypercoagulation in the active period in patients with IBD. Prevention of the facilitating factors such as infections during acute periods of the disease, dehydration, accompanying presence of anaemia and thrombocytosis are essential. Venous thrombosis should be considered in differential diagnosis when symptoms and findings such as headache, cranial nerve involvement, papilloedema and loss of motor function accompany with course of UC.
